Aditya Birla
Aditya Birla Money Limited
  • SENSEX 36471.68419.87 1.16%
  • NIFTY 10739.95121.75 1.15%
Get Quotes
Last Update : 16 Jul
Dr Reddys Laboratories Ltd
(Public, BOM:500038)
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Sector: Pharmaceuticals
Price
Rs. 4,150.85
+2.8%
  • Technical Analysis
  • Benchmark
BSE NSE
  • 1 Day
  • 5 Day
  • 1 Mon
  • 3 Mon
  • 6 Mon
  • 1 Yr
DR.REDDY'S Industry
Average
Market Cap. 67,126.35 9,689.31
Beta 0.47 0.48
EPS (TTM) 177.39 16.54
P/E Ratio (TTM) 22.76 24.48
Dividend Yield (TTM) 0.62 0.49
Institutions 14.35 5.24
Book Value 919.95 
P/B 4.39 
Div(%) 500.00  -
Face Value 5.00 
Related News
[14-Jul-2020] Dr Reddys Laboratories launches OTC store brand version of Nicorette® Lozenges in US market
[14-Jul-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[07-Jul-2020] Dr Reddys Laboratories Ltd - Newspaper Advertisement
[06-Jul-2020] Dr Reddys Laboratories Ltd - Reg. 34 (1) Annual Report
[06-Jul-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Shareholders meeting
[01-Jul-2020] Dr Reddys Laboratories partners with FUJIFLIM and GRA for potential treatment of COVID-19
[01-Jul-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[01-Jul-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[30-Jun-2020] Dr Reddys Laboratories to announce Quarterly Result
[30-Jun-2020] Dr Reddys Laboratories Ltd down for fifth straight session
[29-Jun-2020] Dr Reddys Laboratories allots 14,044 equity shares under ESOS
[29-Jun-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Trading Window
[27-Jun-2020] Dr Reddys Laboratories Ltd - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2020
[27-Jun-2020] Dr Reddys Laboratories Ltd - Closure of Trading Window
[27-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
[25-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication
[23-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[23-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
[19-Jun-2020] Dr. Reddy's Laboratories launches Abiraterone Acetate Tablets in U.S.
[19-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[18-Jun-2020] Dr Reddys Laboratories allots 46,390 equity shares under ESOP
[18-Jun-2020] Dr Reddys Laboratories to conduct AGM
[18-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication
[17-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
[17-Jun-2020] Dr Reddys Laboratories Ltd - Intimation Of Book Closure
[17-Jun-2020] Dr Reddys Laboratories Ltd - Intimation Of Date Of Annual General Meeting
[16-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[13-Jun-2020] Dr. Reddy's Laboratories enters into licensing agreement with Gilead Sciences
[13-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[12-Jun-2020] Dr Reddys Laboratories launches Colchicine Tablets
[12-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[10-Jun-2020] Dr. Reddy's Laboratories completes acquisition of Wockhardt's branded generics business
[10-Jun-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[08-Jun-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Related Party Transactions
[05-Jun-2020] Dr Reddys Laboratories Ltd Rises Around 1%
[05-Jun-2020] Dr Reddys Laboratories Ltd - Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2020.
[01-Jun-2020] Dr Reddys' API Srikakulam Plant receives Establishment Inspection Report
[01-Jun-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[30-May-2020] Dr Reddys Laboratories Ltd - Intimation
[29-May-2020] Dr Reddys Laboratories Ltd gains for third straight session
[28-May-2020] Dr Reddys Laboratories receives EIR for its Medchal-Malkajgiri facility
[28-May-2020] Dr Reddys Laboratories Ltd - Intimation
[28-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[22-May-2020] Dr Reddys Laboratories Ltd - Compliances-Reg.24(A)-Annual Secretarial Compliance
[22-May-2020] Dr Reddys Laboratories Ltd - Compliances-Reg.24(A)-Annual Secretarial Compliance
[22-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - ESOP/ESOS/ESPS
[21-May-2020] Dr Reddys Laboratories Ltd - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
[21-May-2020] Dr Reddys Laboratories Ltd - Grant Of Stock Options
[21-May-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
[21-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[20-May-2020] Dr Reddys Laboratories receives EIR for Bachupally facility
[20-May-2020] Dr Reddy's Laboratories consolidated net profit rises 71.52% in the March 2020 quarter
[20-May-2020] Dr Reddy's Labs spurts after Q4 PAT jumps 76% to 764 cr
[20-May-2020] Board of Dr Reddys Laboratories recommends final dividend
[20-May-2020] Dr Reddys Laboratories Ltd - Outcome Of Board Meeting
[20-May-2020] Dr Reddys Laboratories Ltd - Outcome Of Board Meeting
[20-May-2020] Dr Reddys Laboratories Ltd - Board recommends Final Dividend
[20-May-2020] Dr Reddys Laboratories Ltd - Board Meeting Outcome
[20-May-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
[20-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[19-May-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication
[18-May-2020] Dr. Reddy's Laboratories settles a class action for USD 9 mn
[18-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[16-May-2020] Dr Reddys Laboratories Ltd - Intimation
[13-May-2020] Dr Reddys Laboratories' Srikakulum Plant Unit I receives EIR
[13-May-2020] Dr Reddys Laboratories Ltd - Intimation
[13-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[08-May-2020] Dr Reddys receives EIR from USFDA for API facility at Srikakulam
[08-May-2020] Dr Reddys Laboratories Ltd - Intimation
[08-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[07-May-2020] Dr Reddys Laboratories Ltd - Earnings Call Notification - Q4 And FY20 Results
[07-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[06-May-2020] Dr. Reddy's Laboratories launches Desmopressin Acetate Injection in US market
[06-May-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[06-May-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[06-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[04-May-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Credit Rating
[02-May-2020] Dr Reddys Laboratories receives reaffirmation/ assignment of credit ratings
[01-May-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
[29-Apr-2020] Dr Reddys Laboratories Ltd drops for fifth straight session
[29-Apr-2020] Dr Reddys Laboratories Ltd - Board Meeting Intimation for Audited Financial Results
[27-Apr-2020] Dr Reddys Laboratories launches Fenofibrate Tablets
[27-Apr-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[27-Apr-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[21-Apr-2020] Dr Reddys Laboratories Ltd - Compliance Certificate Under Regulation 40(9) For The Half Year Ended 31.03.2020
[16-Apr-2020] Dr Reddys Laboratories Ltd gains for third straight session
[15-Apr-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[14-Apr-2020] Dr Reddys Laboratories launches generic Evekeo® (amphetamine sulfate) Tablets
[14-Apr-2020] Dr Reddys Laboratories launches generic version of NitroDur® (nitroglycerin) Transdermal Infusion System
[13-Apr-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Disclosure under SEBI Takeover Regulations
[09-Apr-2020] Dr Reddys Laboratories receives EIR for API facility in Telangana
[09-Apr-2020] Dr Reddys Laboratories Ltd - Intimation
[09-Apr-2020] Dr Reddys Laboratories Ltd - Intimation
[09-Apr-2020] Dr Reddys Laboratories Ltd - Statement Of Investor Complaints For The Quarter Ended March 2020
[09-Apr-2020] Dr Reddys Laboratories Ltd - Statement Of Investor Complaints For The Quarter Ended March 2020
[09-Apr-2020] Dr Reddys Laboratories Ltd - Reg 7(3) Compliance Certificate For The Half Year Ended March 31, 2020
[09-Apr-2020] Dr Reddys Laboratories Ltd - Reg 7(3) Compliance Certificate For The Half Year Ended March 31, 2020
[09-Apr-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[08-Apr-2020] Dr Reddys Laboratories Ltd up for third straight session
[28-Mar-2020] Dr Reddys Laboratories to table results
[27-Mar-2020] Board of Dr Reddys Laboratories approves borrowings up to Rs 2000 cr
[27-Mar-2020] Dr Reddys Laboratories Ltd - Outcome Of Board Meeting
[27-Mar-2020] Dr Reddys Laboratories Ltd - Board Meeting Intimation for Audited Financial Results
[27-Mar-2020] Dr Reddys Laboratories Ltd - Board to consider FY20 results & Dividend on May 13, 2020
[27-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Outcome of Board Meeting
[24-Mar-2020] Dr Reddys Laboratories to conduct board meeting
[24-Mar-2020] Board of Dr Reddys Laboratories to consider fund raising by issue of CPs
[23-Mar-2020] Dr Reddys Laboratories Ltd - Board Meeting Intimation for For Raising Of Funds Through Issuance Of Commercial Papers
[20-Mar-2020] Dr Reddys Laboratories launches Pyrimethamine Tablets
[20-Mar-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[20-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[19-Mar-2020] Dr Reddy's Labs launches Naloxone Hydrochloride injection in US
[19-Mar-2020] Dr. Reddy's Laboratories launches Naloxone Hydrochloride Injection USP
[19-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[17-Mar-2020] Dr. Reddy's Labs gains after launching Geodon generic in US
[17-Mar-2020] Dr Reddys Laboratories launches Ziprasidone Mesylate for Injection in US
[17-Mar-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[17-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[16-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[14-Mar-2020] Dr Reddys Laboratories Ltd - Intimation
[12-Mar-2020] Dr Reddys Laboratories allots 8934 equity shares under ESOP
[12-Mar-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
[12-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Allotment of ESOP/ESPS
[06-Mar-2020] Dr Reddys Laboratories announces completion of USFDA audit of API facility unit 5 in Telangana
[06-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[05-Mar-2020] Dr Reddys Laboratories Ltd stays supported
[05-Mar-2020] Dr Reddys Laboratories Ltd - Intimation
[03-Mar-2020] Volumes soar at Cera Sanitaryware Ltd counter
[02-Mar-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[28-Feb-2020] Dr Reddys Laboratories announces conclusion of USFDA audit at Bachupally Plant-3
[28-Feb-2020] Dr Reddys Laboratories Ltd - Intimation
[28-Feb-2020] Dr Reddys Laboratories Ltd - Intimation - Revised
[28-Feb-2020] Dr Reddys Laboratories Ltd - Intimation - Revised
[28-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[27-Feb-2020] Dr. Reddy's Laboratories launches Naproxen and Esomeprazole Magnesium Delayed-Release Tablets
[27-Feb-2020] Dr Reddys Laboratories Ltd extends losing spree
[27-Feb-2020] Dr Reddys Laboratories Ltd - Intimation
[27-Feb-2020] Dr Reddys Laboratories Ltd - Intimation
[27-Feb-2020] Dr Reddys Laboratories Ltd - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
[27-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[24-Feb-2020] Dr Reddy's Labs turns volatile after Duvvada facility gets EIR
[24-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[21-Feb-2020] Dr Reddys Laboratories receives EIR for facility at Duvvada
[20-Feb-2020] Dr Reddys Laboratories Ltd - Intimation under Regulation 30
[19-Feb-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
[17-Feb-2020] Reddy Labs gains after US FDA inspection at Visakhapatnam plant
[17-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[16-Feb-2020] Dr Reddys Laboratories Ltd - Intimation
[14-Feb-2020] Dr Reddys Laboratories Ltd - Intimation
[14-Feb-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
[13-Feb-2020] Dr Reddys Laboratories Ltd up for third straight session
[12-Feb-2020] Dr Reddys Laboratories to acquire select business divisions of Wockhart in India
[12-Feb-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[12-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[10-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
[07-Feb-2020] Dr. Reddy's Laboratories launches Trientine Hydrochloride Capsules
[07-Feb-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[07-Feb-2020] Dr Reddys Laboratories Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release
[04-Feb-2020] Dr Reddys Laboratories Ltd spurts 2.62%
[01-Feb-2020] Dr Reddys Laboratories Ltd - Intimation Regarding Filing Of Form 6K
[01-Feb-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[29-Jan-2020] Dr Reddy's API facility in Srikakulam undergoes USFDA audit
[29-Jan-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Updates
[28-Jan-2020] Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - ESOP/ESOS/ESPS
[27-Jan-2020] Dr Reddy's Laboratories reports consolidated net loss of Rs 538.40 crore in the December 2019 quarter
[27-Jan-2020] Volumes spurt at APL Apollo Tubes Ltd counter
[27-Jan-2020] Dr Reddys Laboratories Ltd - Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2019.
[27-Jan-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
[27-Jan-2020] Dr Reddys Laboratories Ltd - Grant Of Stock Options
[22-Jan-2020] Dr Reddys Laboratories Ltd spurts 0.63%, rises for fifth straight session
[22-Jan-2020] Dr Reddys Laboratories Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
  • CONTACT US

For Broking services call 1800-270-7000 (Toll free) -
(9 am-11:30pm- Mon-Fri &
9am-9pm- Sat & Sun)
For Call N Trade
Call 1800 108 9999 & Dial 1
(9am-11:30pm)

Request a Call Back

Broking & Commodity:
care.stocksandsecurities@
adityabirlacapital.com
Depository Operations:
dpcare.stocksandsecurities@
adityabirlacapital.com

Get to a branch closest to you

 ABML Branches
Locate Us

To reach us for any of our services, SMS the below short codes to 567679

  1. Broking/Distribution SMS: ABM to 567679
  2. Franchisee Partner: ABM to 567679
  3. Portfolio Management Services: ABMCS 567679

Share with us your valuable
feedback

Click Here

ATTENTION INVESTORS :

Securities Broking is through Aditya Birla Money Limited: SEBI Registration No. NSE/BSE/MCX/NCDEX:INZ000172636 ; NSDL /CDSL: IN-DP-17-2015. PMS - INP 000003757, Research Analyst –INH000002145, Investment Adviser - INA000009214. Central Insurance Repository Limited: IRDA/IR2/2014/312. Investments in securities market are subject to market risks, read all the related documents carefully before investing. Please read the risk disclosure document, rights and obligations, guidance note, Do’s and Don’ts and policies and procedure carefully before making any investment decision. Brokerage will not exceed the SEBI prescribed limit. Margins as prescribed by Exchange / SEBI will be applicable.
Corporate Office: Sai Sagar, 2nd & 3rd Floor, Plot No.M-7, Thiru-Vi-Ka (SIDCO) Industrial Estate, Guindy, Chennai 600032. Regd. office: Indian Rayon Compound, Veraval, Gujarat - 362 266 | E-mail: care.stocksandsecurities@adityabirlacapital.com | CIN L65993GJ1995PLC064810 | Tel: +91-44-49490000 / 4949 0200 | Website: stocksandsecurities.adityabirlacapital.com